Recanalisation of cerebral venous thrombosis

Objective: To investigate recanalisation in the first 12 months after cerebral venous thrombosis. Methods: 33 consecutive patients presenting with cerebral venous thrombosis were enrolled in the study. Diagnosis was made by magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) or catheter angiography. Patients were initially treated with intravenous heparin. Warfarin was given for at least four months. Cerebral MRI and MRV were done at four months and repeated after 12 months if venous thrombosis persisted. Outcome was evaluated by the Rankin scale at 12 months. Results: Outcome at 12 months was good, with a median modified Rankin scale score of 0 (range 0 to 2); 27 patients (82%) had no residual deficits. No patient suffered recurrent cerebral venous thrombosis, deep vein thrombosis, or pulmonary embolism during follow up. After four months, all deep cerebral veins and cavernous sinuses, 94% of superior sagittal sinuses, 80% of straight sinuses, 73% of jugular veins, 58% of transverse sinuses, and 41% of sigmoid sinuses had recanalised. No further recanalisation was observed thereafter. Conclusions: The results suggest that recanalisation only occurs within the first four months following cerebral venous thrombosis and not thereafter, irrespective of oral anticoagulation.

[1]  K. M. Einhà Heparin treatment in sinus venous thrombosis. , 1991, Lancet.

[2]  R. Edelman,et al.  Clinical magnetic resonance imaging , 1990 .

[3]  C. Tzourio,et al.  Long-term prognosis in cerebral venous thrombosis. Follow-up of 77 patients. , 1996, Stroke.

[4]  Olle Linder,et al.  A Comparison of Six Weeks with Six Months of Oral Anticoagulant Therapy after a First Episode of Venous Thromboembolism , 1995 .

[5]  Research Committee on Type 1 Diabetes of the Japan Diabetes Society Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism , 1992, The Lancet.

[6]  J. Fiessinger,et al.  Comparison of a once Daily with a twice Daily Subcutaneous Low Molecular Weight Heparin Regimen in the Treatment of Deep Vein Thrombosis , 1998, Thrombosis and Haemostasis.

[7]  H. Schouten,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1988, Stroke.

[8]  K. Schulman,et al.  Cost-effectiveness analyses. , 1995, The New England journal of medicine.

[9]  J. Slattery,et al.  Interobserver agreement for the assessment of handicap in stroke patients. , 1989, Stroke.

[10]  P. Bossuyt,et al.  Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. , 1996, The New England journal of medicine.

[11]  H. Büller,et al.  Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. , 1999, Stroke.

[12]  R R Edelman,et al.  Flow quantification in the superior sagittal sinus using magnetic resonance , 1990, Neurology.

[13]  Researchcommitteeofthebritish Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism*1 , 1992 .

[14]  E. Salzman Treatment of venous thrombosis with subcutaneous heparin. , 1982, The New England journal of medicine.

[15]  R R Edelman,et al.  Cerebral venography with MR. , 1991, Radiology.